Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Aug 20;10(8):1126.
doi: 10.3390/nu10081126.

Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN)

Affiliations
Free PMC article
Randomized Controlled Trial

Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN)

Derek Tobin et al. Nutrients. .
Free PMC article

Abstract

This randomized controlled trial investigated the safety and efficacy of MF4637, a high concentrate omega-3 fatty acid preparation, in correcting the omega-3 fatty acid nutritional deficiency in non-alcoholic fatty liver disease (NAFLD). The primary end point of the study was set as the change of red blood cell (RBC) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) by MF4637. Whether the omega-3 concentrate could lower liver fat was evaluated in a subset of patients. Furthermore, 176 subjects with NAFLD were randomized to receive the omega-3 concentrate (n = 87) or placebo (n = 89) for 24 weeks, in addition to following standard-of-care dietary guidelines. The omega-3 index, omega-6: omega-3 fatty acid ratio and quantitative measurements of RBC EPA and DHA were determined at baseline and study completion. Magnetic resonance imaging of liver fat was conducted in a subset of patients. Administration of high concentrate omega-3 for 24 weeks significantly increased the omega-3 index and absolute values of RBC EPA and DHA, and decreased the RBC omega-6: omega-3 fatty acid ratio (p < 0.0001). A significant reduction in liver fat content was reported in both groups.

Keywords: DHA; EPA; NAFLD; non-alcoholic fatty liver disease; omega-3 fatty acid; omega-3 index.

Conflict of interest statement

D.T. and Y.Q. are employees of BASF AS; M.B.A. is a former employee of BASF AS; P.C.C. is an advisor to BASF AS; J.K.I. has no conflicts to declare.

Figures

Figure 1
Figure 1
CONSORT flow chart of participant flow.
Figure 2
Figure 2
Relationship between change in absolute RBC EPA + DHA and change in liver fat.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. doi: 10.1002/hep.25762. - DOI - PubMed
    1. Levene A.P., Goldin R.D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 2012;61:141–152. doi: 10.1111/j.1365-2559.2011.04145.x. - DOI - PubMed
    1. McCullough A.J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 2004;8:521–533. doi: 10.1016/j.cld.2004.04.004. - DOI - PubMed
    1. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. Q. J. Med. 2010;103:71–83. doi: 10.1093/qjmed/hcp158. - DOI - PMC - PubMed
    1. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The dionysos nutrition and liver study. Hepatology. 2005;42:44–52. doi: 10.1002/hep.20734. - DOI - PubMed

Publication types

MeSH terms

Feedback